CAPRICOR THERAPEUTICS, INC. (CAPR): Results of Operations and Financial Condition
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 capr-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update ● Deramiocel Biologics License Application (BLA) under active FDA review ● HOPE-3 Phase 3 results published in The Lancet; pri
How this was made
The 30-second read
Why it matters
Deramiocel’s FDA review remains active, but the FDA advisory committee voted 3 in favor and 9 against on substantial evidence of effectiveness for the requested cardiomyopathy indication. The company simultaneously points to HOPE-3’s published primary endpoint significance (PUL 2.0, p=0.029) and says the primary endpoint was unaffected by a statistical-model correction, while noting only left ventricular ejection fraction changed.
Market read
Traders get a decision-relevant regulatory snapshot: advisory committee outcome, endpoint-level HOPE-3 publication details including a statistical-model correction, and cash runway plus BIMO inspection status.
What to watch
The filing notes a BIMO Form 483 observation and a statistical-model issue that affected only left ventricular ejection fraction; traders may be over-weighting the 3-9 vote versus the specific endpoint-level outcomes and FDA’s independent review.
Background
This is an SEC 8-K (Item 2.02) with Q2 2026 financial results and a corporate update tied to Deramiocel’s FDA BLA review for Duchenne cardiomyopathy.
Ticker impact
Capricor filed an 8-K with Q2 results plus a Deramiocel FDA BLA update, including a 3-9 advisory vote against cardiomyopathy effectiveness.
Choppy-to-down bias is likely into the next FDA regulatory milestones, with volatility driven by how the FDA weighs the advisory vote versus the published HOPE-3 primary endpoint and secondary cardiac findings.
The filing is a primary disclosure (8-K) and includes multiple decision-relevant items: advisory committee outcome, HOPE-3 publication details, and ongoing FDA review status. However, the recommendation is advisory and non-binding, and the company frames a path forward, limiting directional certainty.
Market effects
Highlights ongoing FDA scrutiny and statistical-model sensitivity in rare-disease cell therapy submissions, which can affect sentiment for similar Duchenne and gene/cell programs.
Limited direct regional spillover; primarily impacts US-listed biotech risk appetite.
HOPE-3 publication in The Lancet and planned Europe/Japan regulatory engagement can influence global rare-disease investor sentiment, but the immediate catalyst is US FDA review.
Counterpoint
The advisory committee was not asked to vote on the HOPE-3 primary endpoint, and the company reports the primary endpoint remained unaffected, suggesting the FDA may still find a viable approval path.
Key entities
- issuerCapricor Therapeutics, Inc.
NASDAQ-listed biotech company developing Deramiocel for Duchenne and related rare diseases; filed Q2 results and regulatory/corporate updates.
- product_candidateDeramiocel
Cell/exosome-based therapy under FDA BLA review; central to the advisory committee outcome and HOPE-3 dataset discussion.
- regulator_advisory_bodyFDA Cellular, Tissue and Gene Therapies Advisory Committee
Voted 3 in favor and 9 against on substantial evidence of effectiveness for Deramiocel in DMD cardiomyopathy.
- clinical_programHOPE-3
Phase 3 study whose full dataset was published in The Lancet; primary endpoint achieved with p=0.029.
- counterpartyNS Pharma
Involved in a US distribution agreement dispute; Capricor withdrew a preliminary injunction motion and expects arbitration to begin this fall.
